Infinity Pharmaceuticals INFI Stock
Infinity Pharmaceuticals Price Chart
Infinity Pharmaceuticals INFI Financial and Trading Overview
| Infinity Pharmaceuticals stock price | 0.0080 USD |
| Previous Close | 0.16 USD |
| Open | 0.17 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 0.16 - 0.18 USD |
| 52 Week Range | 0.12 - 1.76 USD |
| Volume | 1.06M USD |
| Avg. Volume | 746.78K USD |
| Market Cap | 16.14M USD |
| Beta (5Y Monthly) | 1.359859 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.3 USD |
INFI Valuation Measures
| Enterprise Value | -10521288 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.32636362 |
| PEG Ratio (5 yr expected) | 0 |
| Price/Sales (ttm) | 6.0396376 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | -3.938 |
| Enterprise Value/EBITDA | 0.242 |
Trading Information
Infinity Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.359859 |
| 52-Week Change | -75.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.76 USD |
| 52 Week Low | 0.12 USD |
| 50-Day Moving Average | 0.17 USD |
| 200-Day Moving Average | 0.6 USD |
INFI Share Statistics
| Avg. Volume (3 month) | 746.78K USD |
| Avg. Daily Volume (10-Days) | 408.93K USD |
| Shares Outstanding | 89.9M |
| Float | 81.63M |
| Short Ratio | 1.07 |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 28.78% |
| Shares Short | 601.63K |
| Short % of Float | 0.67% |
| Short % of Shares Outstanding | 0.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1644.61% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -53.57% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 2.67M USD |
| Revenue Per Share (ttm) | 0.03 USD |
| Quarterly Revenue Growth (yoy) | 12.09% |
| Gross Profit (ttm) | -31381000 USD |
| EBITDA | -43502000 USD |
| Net Income Avi to Common (ttm) | -42978000 USD |
| Diluted EPS (ttm) | -0.46 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 25.74M USD |
| Total Cash Per Share (mrq) | 0.29 USD |
| Total Debt (mrq) | 777K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.512 |
| Book Value Per Share (mrq) | -0.317 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -41472000 USD |
| Levered Free Cash Flow (ttm) | -24454500 USD |
Profile of Infinity Pharmaceuticals
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 1100 Massachusetts Avenue |
| ZIP | 02138 |
| Phone | (617) 453-1000 |
| Website | https://www.infi.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 30 |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
Q&A For Infinity Pharmaceuticals Stock
What is a current INFI stock price?
Infinity Pharmaceuticals INFI stock price today per share is 0.0080 USD.
How to purchase Infinity Pharmaceuticals stock?
You can buy INFI shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Infinity Pharmaceuticals?
The stock symbol or ticker of Infinity Pharmaceuticals is INFI.
Which industry does the Infinity Pharmaceuticals company belong to?
The Infinity Pharmaceuticals industry is Biotechnology.
How many shares does Infinity Pharmaceuticals have in circulation?
The max supply of Infinity Pharmaceuticals shares is 90.76M.
What is Infinity Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Infinity Pharmaceuticals PE Ratio is 0.00000000 now.
What was Infinity Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Infinity Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Infinity Pharmaceuticals company belong to?
The Infinity Pharmaceuticals sector is Healthcare.
Infinity Pharmaceuticals INFI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
- {{ link.label }} {{link}}